How effective is tofacitinib/Shangjie in treating rheumatoid arthritis?

Tofacitinib/Shangjie（Tofacitinib) is an innovative oral JAK inhibitor, mainly used for patients with moderately to severely active rheumatoid arthritis (RA), especially for those who have insufficient response or poor tolerance to traditional disease-modifying antirheumatic drugs (DMARDs). Its mechanism of action is by inhibiting the Janus kinase (JAK) signaling pathway, thereby blocking the signal transduction of a variety of pro-inflammatory cytokines, including interleukins (IL-6, IL-2) and the interferon family. This broad-spectrum modulation of inflammation allows tofacitinib to effectively reduce joint inflammation, pain and swelling, while delaying the process of joint destruction.

Tofacitinib has shown significant efficacy in multi-center clinical studies and real-world applications. Patients may experience relief from pain and morning stiffness within a few weeks of taking the medication, and their joint function gradually improves. Compared with traditional biologics, the convenience of oral administration of tofacitinib significantly improves patient compliance, and is more suitable for daily use, especially for patients who require long-term maintenance treatment. When used in combination with methotrexate or other DMARDs, tofacitinib can enhance the anti-inflammatory effect and improve the prognosis of long-term joint damage to a certain extent.

The efficacy of tofacitinib is not only reflected in the improvement of symptoms, but also includes the suppression of bone erosion and joint structure destruction on imaging. Some long-term follow-up studies have shown that continued use of tofacitinib can slow down the progression of joint damage shown on X-rays and MRI, and provide support for patients to maintain their ability to perform daily activities. At the same time, tofacitinib has a rapid onset of action, which is one of the important reasons why it has attracted clinical attention. It allows patients to achieve significant symptom relief in a short period of time and improve their quality of life.

In actual clinical application, the efficacy evaluation of tofacitinib is usually combined with disease activity score (DAS28), patient self-assessment and joint imaging changes. Doctors will adjust the dose based on the patient's disease activity, past medication use and tolerance to achieve precise treatment.

Reference materials:https://www.xeljanz.com/